TELESAS: Usefulness of a Telemedicine System for OSA Patients Follow-up With High Cardiovascular Risk

Sponsor
Initiative Pour la Sante (Industry)
Overall Status
Terminated
CT.gov ID
NCT01226641
Collaborator
(none)
107
14
2
30
7.6
0.3

Study Details

Study Description

Brief Summary

The aim of this study is to determine the usefulness of a telemedicine system for the follow-up of OSA patients with a high cardiovascular risk. Our hypothesis is that the telemedicine system will enhance compliance and thus reduce self-measured blood pressure.

Condition or Disease Intervention/Treatment Phase
  • Device: Telemedicine
  • Device: Standard care
N/A

Detailed Description

The obstructive sleep apnea syndrome (OSAS) corresponds to repeated epochs of complete or incomplete pharynx collapses occurring during sleep. The Continuous Positive Airway Pressure is the gold standard treatment for OSAS. It consists of air insufflation in upper airways with a pressure of about 5 to 15 cm of water with a facial or nasal mask. CPAP treatment reduces cardiovascular morbi-mortality.

OSAS is associated with cardiovascular mortality. A dose response effect exists between severity and arterial blood pressure. A recent meta-analysis has shown in unselected OSAS patients with or without hypertension, treated or non-treated for hypertension, CPAP reduces 24 h ambulatory blood pressure of approximately 2 mmHg. This decrease corresponds to a significant reduction in cardiovascular risk.

The aim of the present study is to include OSAS patients with a high cardiovascular risk and to measure the effect of CPAP on home measurements of arterial blood pressure. This controlled randomized trial will compare the effect CPAP on arterial blood pressure in a group with a telemedicine system versus a group with standard home care CPAP treatment.

An interim analysis will be carried out when 100 patients have been included in the study.

Study Design

Study Type:
Interventional
Actual Enrollment :
107 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Usefulness of a Telemedicine System for OSA Patients Follow-up With High Cardiovascular Risk
Study Start Date :
Jul 1, 2009
Actual Primary Completion Date :
Jan 1, 2012
Actual Study Completion Date :
Jan 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: Telemedecine

CPAP treatment with telemedicine system

Device: Telemedicine
CPAP treatment with telemedicine system

Active Comparator: Standard Care

Standard care, including CPAP

Device: Standard care
Standard care, including CPAP

Outcome Measures

Primary Outcome Measures

  1. Home Arterial Blood Pressure [Home arterial Blood Pressure is assessed at week 1]

    the primary outcome is assessed at weeks 1 and 16 for the both groups, moreover home arterial blood pressure is assessed each day, 2 times : morning and afternoon in the telemedicine group.

  2. Home Arterial Blood Pressure [Home arterial Blood Pressure is assessed at week 16]

    the primary outcome is assessed at weeks 1 and 16 for the both groups, moreover home arterial blood pressure is assessed each day, 2 times : morning and afternoon in the telemedicine group.

Secondary Outcome Measures

  1. CPAP compliance [week 16]

    the CPAP compliance is assessed in the two groups at week 16

  2. Sleepiness [weeks 1 and 16]

    Sleepiness is assessed with Epworth Sleepiness Scale at weeks 1 and 16 for the two groups

  3. Physical Activity [week 1]

    Daily Physical Activity is assessed with an accelerometer (Sensewear Armband, Bodymedia) at weeks 1 and 16 in the two groups. Daily expenditure, steps number, daily METs are assessed.

  4. Quality of Life [week 16]

    Quality of life is assessed with SF-12 questionnaire at weeks 1 and 16 in the two groups.

  5. Cardiovascular risk SCORE [Week 1]

    The cardiovascular risk SCORE is assessed at weeks 1 and 16 in the two groups.

  6. Sleepiness [week 16]

    Sleepiness is assessed with Epworth Sleepiness Scale at weeks 1 and 16 for the two groups

  7. Physical Activity [week 16]

    Daily Physical Activity is assessed with an accelerometer (Sensewear Armband, Bodymedia) at weeks 1 and 16 in the two groups. Daily expenditure, steps number, daily METs are assessed.

  8. Quality of Life [week 1]

    Quality of life is assessed with SF-12 questionnaire at weeks 1 and 16 in the two groups.

  9. Cardiovascular risk SCORE [Week 16]

    The cardiovascular risk SCORE is assessed at weeks 1 and 16 in the two groups.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 to 85 years old men and women

  • stable patient

  • BMI<40kg/m²

  • OSA patients diagnosed with polysomnography or polygraphy

  • SCORE>5% and/or cardiovascular disease pas history :

  • transient ischemic attack, stroke, cerebral haemorrhagy

  • myocardial infraction, angor, coronary revascularization, arteriopathy, aortic aneurism

Exclusion Criteria:
  • central sleep apnea syndrome

  • SCORE<5%

  • cardiac failure

  • past history of hypercapnic chronic respiratory failure

  • past history of severe or intercurrent pathology which can not allow the patient follow-up

  • Incapacitated patients in accordance with article L 1121-6 of the public health code

  • patients taking part in another clinical trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 Liberal Office Boulogne Billancourt France 92100
2 Clermont Tonerre military hospital Brest France 29200
3 Liberal Office Chambery France 73000
4 Liberal Office Grenoble France 38000
5 University Hospital Grenoble France 38000
6 Liberal Office Montigny les Metz France 57950
7 Liberal Office Nancy France 54000
8 Cornouaille Hospital Quimper France 29107
9 Montier Polyclinic St Andre les Vergers France 10120
10 Hospitalor Hospital St Avold France 57500
11 Liberal Office St Jean de Maurienne France 73300
12 Liberal Office St Martin les Boulogne France 62280
13 Liberal Office StIsmier France 38330
14 Liberal Office Strasbourg France 67000

Sponsors and Collaborators

  • Initiative Pour la Sante

Investigators

  • Principal Investigator: Jean Louis PEPIN, Prof, PhD, University Hospital, Grenoble

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Initiative Pour la Sante
ClinicalTrials.gov Identifier:
NCT01226641
Other Study ID Numbers:
  • InitiativePS-TELESAS
First Posted:
Oct 22, 2010
Last Update Posted:
Jan 17, 2013
Last Verified:
Jan 1, 2013

Study Results

No Results Posted as of Jan 17, 2013